Business Context and Reporting Period
Company: Intelligent Bio Solutions Inc. (INBS)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Three and nine months ended March 31, 2025
Business Overview: A medical technology company focused on non-invasive testing solutions. Operations are split between the commercially available Intelligent Fingerprinting Products (IFPG) segment and the development-stage Biosensor Platform Technology (BPT) segment. The company is classified as a smaller reporting company and an emerging growth company.
Key Financial Metrics
| Metric | Three Months Ended Mar 31, 2025 | Nine Months Ended Mar 31, 2025 |
|---|---|---|
| Revenue | $728,867 | $2,208,648 |
| Gross Profit | $341,368 | $911,282 |
| Gross Margin | 46.84% | 41.26% |
| Net Loss (Attributable to INBS) | $(2,543,526) | $(7,478,629) |
| Net Loss Per Share (Basic/Diluted) | $(0.44) | $(1.59) |
| Cash and Cash Equivalents | $2,807,112 | $2,807,112 (as of Mar 31, 2025) |
| Working Capital | $542,946 | $542,946 (as of Mar 31, 2025) |
| Accumulated Deficit | $(59,442,961) | $(59,442,961) (as of Mar 31, 2025) |
Material Changes vs. Prior Period
- Revenue: Decreased 11.5% year-over-year (YoY) for the three months ended March 31, 2025, and 7.4% for the nine-month period. The decline is attributed to instability in the construction sector reducing reader sales, partially offset by a strategic shift toward higher-margin cartridge sales.
- Gross Profit: Increased significantly despite lower revenue. Gross profit rose 91.3% YoY for the quarter and 49.4% for the nine-month period. Margins improved from 21.67% to 46.84% (quarterly) due to a favorable sales mix (cartridges have ~90% contribution margin vs. ~67% for readers) and reduced direct labor/material costs.
- Government Support: Increased 106.7% YoY for the quarter to $173,271, driven by R&D tax refunds and grant income.
- Operating Expenses: Total operating expenses decreased slightly YoY for the quarter but increased for the nine-month period, primarily due to higher development and regulatory approval expenses ($1.81M vs $0.92M) related to FDA 510(k) clinical study plans.
- Liquidity: Cash balances decreased from $6.30M (June 30, 2024) to $2.81M (March 31, 2025) due to operating cash burn, partially offset by financing activities.
Guidance, Outlook, Risks, and Unusual Items
Capital Raising and Liquidity
The company raised approximately $2.65M in a February 2025 underwritten public offering and $1.49M via an At-The-Market (ATM) offering through March 31, 2025. Despite these efforts, management has disclosed a substantial doubt about the company's ability to continue as a going concern for the next 12 months. Current cash reserves are deemed insufficient to fund the operating plan without additional financing.
Operational Updates
- Product Expansion: Integrated Arabic language support and expanded distribution in Spain and Andorra. Secured 35 new accounts, bringing total active customers to over 450 in 24 countries.
- Regulatory Progress: Completed a method comparison clinical study with CenExel for the FDA 510(k) submission.
- Biosensor Platform (BPT): Development is postponed pending the liquidation of the licensor (LSBD) and finalization of new licensing terms with the University of Newcastle.
Risks and Contingencies
- Grant Refund Risk: The company failed to meet all milestones for an Australian government grant by the March 28, 2025 deadline. A liability of $2,278,681 is recorded for the potential refund of grant funds.
- Internal Controls: Management identified material weaknesses in internal controls over financial reporting, citing a lack of documented policies, insufficient review procedures, and limited accounting personnel.
- Going Concern: Continued reliance on equity financing is required; failure to raise capital could force the company to delay research or cease operations.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $2.81M cash balance against the burn rate and the timeline for securing additional capital.
- Grant Liability: Confirm the final settlement terms regarding the Australian government grant refund and the impact on future cash flows.
- Internal Controls: Review the progress of the remediation plan for material weaknesses in financial reporting controls.
- BPT Licensing: Monitor the status of the LSBD liquidation and the negotiation of new licensing terms with the University of Newcastle.
- Revenue Mix: Assess the sustainability of the improved gross margins driven by the shift to cartridge sales versus the decline in reader sales.